Retraction: Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma by null null
CORRECTION
published: 07 October 2016
doi: 10.3389/fnins.2016.00465
Frontiers in Neuroscience | www.frontiersin.org 1 October 2016 | Volume 10 | Article 465
Approved by:
Arjan Blokland,
Maastricht University, Netherlands
*Correspondence:
Frontiers Editorial Office
editorial.office@frontiersin.org
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Neuroscience
Received: 27 September 2016
Accepted: 27 September 2016
Published: 07 October 2016
Citation:
Frontiers Editorial Office (2016)
Retraction: Atorvastatin May Attenuate
Recurrence of Chronic Subdural
Hematoma. Front. Neurosci. 10:465.
doi: 10.3389/fnins.2016.00465
Retraction: Atorvastatin May
Attenuate Recurrence of Chronic
Subdural Hematoma
Frontiers Editorial Office*
A retraction of the Original Research Article
Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
by Liu, H., Luo, Z., Liu, Z., Yang, J., and Kan, S. (2016). Front. Neurosci. 10:303. doi:
10.3389/fnins.2016.00303
The Journal and Authors retract the 28 June 2016 article cited above for the following reasons
provided by the Authors:
In one of our collaborating centers (The People’s Hospital of AnQiu City), 38 patients were
enrolled in an atorvastatin group. Among them, 26 patients lost to follow-up were categorized
and analyzed as “non-recurrence group.” It was a fundamental error and thus we must retract this
article. We apologize for any inconvenience caused by the retraction of this article.
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